Abstract
Serum β(2)-microglubin (β(2)-m) levels were measured in oral carcinoma patients and compared with normal healthy controls. It was observed that there was a significant rise in serum β(2)-microglobulin in oral carcinoma patients. Progressively higher values were obtained as the cancer advanced clinically. Therefore the estimation of serum β(2)-microglobulin may be useful as one of a battery of tests in the assessment of oral carcinoma patients.